title: Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
abstract: Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC revealed a spherical shape with a diameter <300 nm. In vitro biological studies demonstrated that sorafenib loaded into NLC had enhanced anti-tumor activity compared to that of free drug. This finding raises hope in terms of future drug delivery strategy of sorafenib loaded NLC, that can be useful for therapeutic application in HCC.
authors.affiliation: Istituto per lo Studio dei Materiali Nanostrutturati, U.O.S. di Palermo, Consiglio Nazionale delle Ricerche, via Ugo La Malfa, 153 90146 Palermo, Italy. Electronic address: marialuisa.bondi@ismn.cnr.it.
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Bondì
authors.affiliation: Laboratory of Biocompatible Polymers-Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF) - Università degli Studi di Palermo -via Archirafi, 32-90123 Palermo - Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Botto
authors.affiliation: Laboratory of Biocompatible Polymers-Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF) - Università degli Studi di Palermo -via Archirafi, 32-90123 Palermo - Italy.
authors.forename: Erika
authors.initials: E
authors.lastname: Amore
authors.affiliation: Istituto di Biomedicina e Immunologia Molecolare "A. Monroy", Consiglio Nazionale delle Ricerche, via Ugo La Malfa, 153, 90146 Palermo, Italy.
authors.forename: Maria Rita
authors.initials: MR
authors.lastname: Emma
authors.affiliation: Istituto di Biomedicina e Immunologia Molecolare "A. Monroy", Consiglio Nazionale delle Ricerche, via Ugo La Malfa, 153, 90146 Palermo, Italy; Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Piazza delle Cliniche, 2 90127 Palermo, Italy.
authors.forename: Giuseppa
authors.initials: G
authors.lastname: Augello
authors.affiliation: Laboratory of Biocompatible Polymers-Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF) - Università degli Studi di Palermo -via Archirafi, 32-90123 Palermo - Italy.
authors.forename: Emanuela Fabiola
authors.initials: EF
authors.lastname: Craparo
authors.affiliation: Istituto di Biomedicina e Immunologia Molecolare "A. Monroy", Consiglio Nazionale delle Ricerche, via Ugo La Malfa, 153, 90146 Palermo, Italy.
authors.forename: Melchiorre
authors.initials: M
authors.lastname: Cervello
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002210:Caprylates / Q000737:chemistry; D002470:Cell Survival; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D065546:Drug Liberation; D006461:Hemolysis; D056945:Hep G2 Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D053758:Nanoparticles / Q000737:chemistry*; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D010316:Particle Size; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D000077157:Sorafenib; D014280:Triglycerides / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D002210:Caprylates; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D008055:Lipids; D010671:Phenylurea Compounds; D014280:Triglycerides; D009536:Niacinamide; C022834:miglyol 812; D000077157:Sorafenib; C005859:tripalmitin
keywords: Angiogenesis inhibitor; Drug release; Hepatocarcinoma; Nanostructured lipid carriers; Sorafenib